Dementia

Driving change through evidence-based research

Dementia affects millions of lives across the UK, with profound implications for individuals, families, and society as a whole. At CF, we’re committed to generating the robust evidence needed to shape policy, influence decision-makers, and drive meaningful change in how we approach dementia care and support.

Our approach to dementia research combines rigorous methodology with compelling storytelling. We understand that behind every statistic is a human story, and our work bridges the gap between complex healthcare data and the lived experiences of those affected by dementia. We’ve partnered with organisations such as the Alzheimer’s Society to provide critical insights into the costs, challenges, and urgent need for policy intervention in the dementia landscape.

Our reports

Recent insights

Building on the success of our landmark report with the Alzheimer’s Society, we continue to evolve our research, exploring new findings and emerging areas of concern within the dementia landscape.

Our research in the news

Donanemab-azbt receives marketing authorization in Great Britain

Eli Lilly and Company announced today that the MHRA has granted marketing authorization for donanemab for the treatment of mild cognitive impairment and mild dementia due to Alzheimer’s Disease

Annual cost of dementia is set to double in the next 15 years to an astonishing £90bn, report reveals

Analysis shows the cost of dealing with the disease has already reached £42 billion a year.

Cost of dementia to UK could almost double to £91bn by 2040, study finds

‘Colossal’ costs of disease include health and social care as well as societal costs such as legal fees and lost economic consumption

Dementia to cost economy £90bn by 2040 as population ages

Bill will more than double unless action taken, research shows

Our expert team

Our expert dementia team combines deep clinical knowledge with advanced research methodologies, bringing together specialists in health economics, policy analysis, and dementia care pathways. This multidisciplinary expertise enables us to tackle the complex challenges of dementia research from multiple angles, ensuring our findings are practically applicable to real-world policy decisions.

Ben Richardson

Managing Partner, Life Sciences

Dorinda Hickey

Advisor

Jacqueline Roberts

Manager

Beena Mistry

Consultant

Jack Rowlandson

Consultant

 

 

 

To speak to one of our specialists about our work on Dementia, contact us today or email us at [email protected].